How to Read a Peptide Purity Test: HPLC, Mass Spectrometry and COA Interpretation for UK Researchers (2026)

When sourcing research peptides, a Certificate of Analysis (COA) is the primary document through which a supplier communicates quality data about a batch. But a COA is only as useful as the researcher’s ability to interpret it — and many researchers who receive COAs have not been trained in analytical chemistry. This guide explains the key analytical tests found on peptide COAs: what they measure, how to read the results, and what red flags to look for.

Why Purity Testing Matters in Peptide Research

Synthetic peptides are manufactured by solid-phase peptide synthesis (SPPS) — a stepwise process of assembling amino acids on a resin support, deprotecting functional groups, and cleaving the completed peptide. While SPPS is highly controlled, it inevitably produces by-products: truncated sequences (synthesis failures at intermediate steps), deletion sequences (missed amino acid couplings), oxidised residues, and deamidation products. Without analytical testing, a vial labelled “BPC-157” might contain 85% intact BPC-157, 10% related impurities, and 5% solvent residuals — a composition that would confound research results.

Purity testing quantifies these impurities. Identity testing confirms that what was synthesised is actually the intended sequence. Together, these analytical methods provide the evidence base for concluding that a peptide batch is suitable for research use.

High-Performance Liquid Chromatography (HPLC): The Purity Standard

HPLC is the primary method for determining peptide purity. It separates the components of a sample based on their differential affinity for a stationary phase (column packing material) and a mobile phase (solvent system moving through the column).

How HPLC works for peptides: Reverse-phase HPLC (RP-HPLC) is the standard for peptide analysis. The stationary phase is a non-polar alkyl chain (typically C18 — octadecyl) bonded to silica beads. The mobile phase is typically an aqueous/organic gradient — starting with high-water (polar) conditions and moving to high-organic (typically acetonitrile) conditions. Polar compounds (including most impurities) elute early; hydrophobic peptides elute later as the organic proportion increases. The target peptide is identified by its retention time — the time at which it elutes from the column under standard gradient conditions.

Detection: Peptides absorb UV light at 214–220 nm (due to the peptide bond) and at 280 nm (if aromatic residues like Trp, Tyr, Phe are present). UV absorbance at 214 nm is the standard detection wavelength for most peptide purity analyses.

The chromatogram: The HPLC output is a chromatogram — a plot of UV absorbance (y-axis) against time (x-axis). Each peak represents a compound eluting from the column. The main peak is the target peptide. Smaller peaks before or after the main peak represent impurities.

Purity calculation: Purity is reported as the percentage of total peak area accounted for by the main peak: (main peak area / total area of all peaks) × 100. A purity of 98% means the main peptide peak comprises 98% of all UV-absorbing material detected — and approximately 2% is other compounds.

Reading HPLC Results on a COA

On a COA, look for the HPLC purity result expressed as a percentage. Quality benchmarks:

≥98% purity: Research grade. Appropriate for most cell culture and animal studies where high reproducibility and low confound risk are required. This is the standard demanded by reputable research peptide suppliers.

95–97% purity: Acceptable for some applications but not optimal. At this purity level, impurities are significant enough to warrant consideration in study design — particularly in sensitive cell-based assays where low-concentration effects may be confounded by impurities.

<95% purity: Below research grade. Not appropriate for rigorous scientific work. Impurity levels are high enough to substantially confound results and make batch-to-batch reproducibility difficult.

Red flags on HPLC data:
No chromatogram image provided — a legitimate supplier showing “99.1%” without the actual chromatogram is unverifiable. The COA should include the chromatogram.
Multiple large secondary peaks — indicates significant impurities regardless of the headline percentage.
Single narrow peak with unusually flat baseline — may indicate processing or smoothing of the data.
Retention time not specified — without knowing the expected retention time for the target peptide, the main peak cannot be confirmed as the correct compound.

Mass Spectrometry (MS): Identity Confirmation

HPLC tells you what proportion of your sample is the main compound — but it does not confirm what that main compound actually is. A peak with the right retention time could theoretically be a related peptide with similar hydrophobicity. Mass spectrometry provides identity confirmation by measuring molecular mass directly.

How MS works: Mass spectrometry ionises molecules and separates them by their mass-to-charge ratio (m/z). For peptides, the most common ionisation method is electrospray ionisation (ESI) — a soft ionisation technique that produces multiply-charged ions from the peptide sequence without fragmenting it. The instrument measures the m/z of these ions, and the molecular weight is calculated from the charge state distribution.

Expected vs observed mass: Every peptide has a precisely calculable monoisotopic molecular mass based on its amino acid sequence and any chemical modifications (PEGylation, acetylation, etc.). The MS result should show an observed mass within a very small tolerance of the calculated theoretical mass — typically ±0.1 Da or ±0.02% for high-resolution instruments.

For example, BPC-157 (sequence: GEPPPGKPADDAGLV) has a theoretical molecular weight of approximately 1419.5 Da. A COA MS result showing an observed mass of 1419.5 ± 0.1 Da confirms the correct molecular composition. An observed mass differing by even a few daltons suggests a sequence error, modification, or wrong compound entirely.

Reading Mass Spectrometry Results on a COA

Look for: Theoretical MW (the expected mass calculated from sequence), Observed MW (the measured mass from the MS instrument), and the difference or confirmation statement. A well-formatted COA will state both values and confirm they match within tolerance.

What MS can confirm: Molecular formula composition. Whether a modification (e.g. acetylation adds 42 Da, PEGylation adds the MW of the PEG chain) is present as claimed.

What MS cannot confirm: Sequence order of amino acids — a scrambled sequence with identical amino acids would have the same molecular mass. Stereochemistry — a D-amino acid variant would have the same mass as the L-amino acid version. This is why MS alone is insufficient for full identity confirmation; it must be combined with HPLC (which would show different retention times for sequence variants) or advanced MS/MS fragmentation analysis.

Red flags on MS data:
Mass reported to only 1 decimal place on a small peptide — suggests low-resolution instrument.
Large mass difference from theoretical — any discrepancy exceeding 1 Da on a peptide <3000 Da suggests a problem.
No mass spectrum shown — just a number without the spectrum.

MS/MS Fragmentation: Sequence Confirmation

Tandem mass spectrometry (MS/MS or MS²) fragments the peptide ions in the gas phase and analyses the fragment masses. Because fragmentation follows the peptide backbone in predictable patterns, the resulting fragment ions (b-ions from the N-terminus, y-ions from the C-terminus) can be used to confirm not just the molecular mass but the actual amino acid sequence order. This is the gold standard for peptide identity — it confirms both the composition and the sequence.

Very few commercial research peptide suppliers provide MS/MS data on routine COAs — it is typically reserved for pharmaceutical-grade materials and advanced research settings. However, some premium suppliers do provide it on request for critical batches. If sequence confirmation is essential for your research, this is the analysis to request.

Additional Analytical Tests on Quality COAs

Water content (Karl Fischer titration): Lyophilised peptides absorb moisture from the atmosphere. If not corrected for, water content inflates the apparent mass of the vial contents — meaning the actual peptide content is lower than the labelled amount. Quality COAs report water content (typically 5–15% for lyophilised peptides) so researchers can calculate the true peptide content. Without this correction, dosing calculations are systematically inaccurate.

Residual solvents: SPPS uses organic solvents (DMF, DCM, TFA) that must be removed by evaporation and lyophilisation. Residual solvent testing (typically by GC headspace analysis) confirms that dangerous solvent residuals are below ICH Q3C guideline limits. TFA residuals are particularly common and at high concentrations can affect cell viability assays.

Bacterial endotoxins (LAL test): Lipopolysaccharide endotoxins from gram-negative bacteria are potent pyrogens and immune activators. In in vivo research, even low-level endotoxin contamination can confound results — particularly in immune-related research endpoints. The Limulus Amoebocyte Lysate (LAL) test quantifies endotoxin content. For in vivo research, endotoxin levels should be <1 EU/mg; for cell culture work, <0.1 EU/ml in the reconstituted dose is preferred. Many research peptide COAs do not include endotoxin testing — if you are conducting in vivo or sensitive cell-based work, this is a critical test to request.

Amino acid analysis (AAA): Acid hydrolysis of the peptide releases individual amino acids, which can then be quantified chromatographically. This confirms the amino acid composition (though not sequence order) and provides an orthogonal identity check to MS. It can also provide an accurate absolute quantification of peptide content independent of UV absorbance (which can be affected by modifications).

Batch-Specific vs Generic COAs

A critical distinction: a genuine COA is batch-specific — the document should reference the specific lot/batch number of the product being supplied, and the analytical data on that COA should have been generated from testing of that specific batch. Generic COAs — where the same document is reused across multiple batches, or where a reference standard batch was tested but not the supplied batch — are a serious quality concern.

Verify batch specificity by checking that the COA includes: a specific lot/batch number matching the vial, an analysis date, and ideally a laboratory report number. If a supplier cannot provide a batch-specific COA for your order, treat the quality data as unverified.

Third-Party Testing vs In-House Testing

The most credible COAs are issued by independent accredited analytical laboratories — not by the peptide supplier’s own in-house team. Third-party testing removes the conflict of interest inherent in a supplier testing their own product. Look for: the name of the analytical laboratory (not the peptide supplier), an accreditation statement (ISO 17025 accreditation for the testing laboratory), and a report reference number that could theoretically be traced back to the lab.

Many reputable research peptide suppliers use third-party labs; some conduct in-house testing with publication of laboratory credentials. Either can be acceptable, but third-party testing is the gold standard for research-grade materials.

Summary: What a Research-Grade COA Should Include

For research use, a complete quality COA should contain: HPLC purity ≥98% with chromatogram, MS identity confirmation with both theoretical and observed masses, water content (for accurate dosing), and batch/lot number with analysis date from an identifiable laboratory. Bonus elements for sensitive research: residual solvent data, endotoxin testing results, and MS/MS sequence confirmation. Any COA missing the core elements should be treated with scepticism before use in research.